Hapten-directed targeting to single-chain antibody receptors

Cancer Gene Therapy

Volumn 11, Issue 5, 2004, Pages 380-388

  Cheng, Tian Lu ^a   Liao, Kuang Wen ^b   Tzou, Shey Cherng ^c   Cheng, Chiu Min ^a   Chen, Bing Mae ^c   Roffler, Steve R ^c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Bystander killing; Chimeric protein; Hapten; phOx; Prodrug; Single chain antibody

Indexed keywords

4 [BIS(2 CHLOROETHYL)AMINO]PHENOL; 4 ETHOXYMETHYLENE 2 PHENYL 2 OXAZOLIN 5 ONE; 4 ETHOXYMETHYLENE 2 PHENYL 2 OXAZOLIN 5 ONE POLYETHYLENE GLYCOL MODIFIED BETA GLUCURONIDASE; BETA GLUCURONIDASE; GLUCURONIDE; HAPTEN; OXAZOLINE DERIVATIVE; POLYETHYLENE GLYCOL MODIFIED BETA GLUCURONIDASE; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BYSTANDER EFFECT; CELL KILLING; CELL POPULATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GLUCURONIDATION; HAPTEN CARRIER COMPLEX; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RECEPTOR BINDING; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TARGET CELL; TRANSGENE; TUMOR GROWTH;

ANILINE MUSTARD; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GENE EXPRESSION; HAPTENS; IMMUNOTHERAPY; INJECTIONS, INTRAVENOUS; MELANOMA; MICE; NEOPLASMS, EXPERIMENTAL; OXAZOLES; POLYETHYLENE GLYCOLS; PRODRUGS; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 2342620199     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700712     Document Type: Article

References (36)

1. Hank JA, Albertini MR, Sondel PM. Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant disease. Cancer Chemother Biol Response Modif. 1999;18:210-222.
2. Trail PA, Bianchi AB. Monoclonal antibody drug conjugates in the treatment of cancer. Curr Opin Immunol. 1999;11:584-588.
3. Buchsbaum DJ. Experimental radioimmunotherapy. Semin Radiat Oncol. 2000;10:156-167.
4. Hayden MS, Grosmaire LS, Norris NA, et al. Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen. Tissue Antigens. 1996;48:242-254.
5. Rode HJ, Moebius U, Little M. T cell activation by monoclonal antibodies bound to tumor cells by a cell surface displayed single-chain antibody. J Immunol Methods. 1999;224:151-160.
6. Liao KW, Lo YC, Roffler SR. Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells. Gene Therapy. 2000;7:339-347.
7. Ye Z, Hellstrom I, Hayden-Ledbetter M, et al. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med. 2002;8:343-348.
8. Liao KW, Chen BM, Liu TB, et al. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity. Cancer Gene Ther. 2003;10:779-790.
9. Griffiths GM, Berek C, Kaartinen M, et al. Somatic mutation and the maturation of immune response to 2-phenyl oxazolone. Nature. 1984;312:271-275.
10. Hoogenboom HR, Griffiths AD, Johnson KS, et al. Multisubunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 1991;19:4133-4137.
11. Farinas J, Verkman AS. Receptor-mediated targeting of fluorescent probes in living cells. J Biol Chem. 1999;274:7603-7606.
12. Chesnut JD, Baytan AR, Russell M, et al. Selective isolation of transiently transfected cells from a mammalian cell population with vectors expressing a membrane anchored single-chain antibody. J Immunol Methods. 1996;193: 17-27.
13. Rode HJ, Little M, Fuchs P, et al. Cell surface display of a single-chain antibody for attaching polypeptides. Biotechniques. 1996;21:650-658.
14. Liao KW, Chou WC, Lo YC, et al. Design of transgenes for efficient expression of active chimeric proteins on mammalian cells. Biotechnol Bioeng. 2001;73:313-323.
15. Roffler SR, Wang SM, Chern JW, et al. Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol. 1991;42:2062-2065.
16. Cheng TL, Chen BM, Chan LY, et al. Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs. Cancer Immunol Immunother. 1997;44:305-315.
17. Morrison SL, Porter SB, Trinh KR, et al. Variable region domain exchange influences the functional properties of IgG. J Immunol. 1998;160:2802-2808.
18. Cheng TL, Wu PY, Wu MF, et al. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug Chem. 1999;10:520-528.
19. Stocks SJ, Jones AJ, Ramey CW, et al. A fluorometric assay of the degree of modification of protein primary amines with polyethylene glycol. Anal Biochem. 1986;154:232-234.
20. Stribbling SM, Friedlos F, Martin J, et al. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum Gene Ther. 2000;11:285-292 (FTXT: Full text from Swets).
21. Cheng TL, Chou WC, Chen BM, et al. Characterization of an antineoplastic glucuronide prodrug. Biochem Pharmacol. 1999;58:325-328.
22. Baese HJ, Havsteen BH. 4-alkylidene oxazolones as substrates and inhibitors for sensitive assays of the normality of active sites and the catalytic properties of hydrolases. Biochim Biophys Acta. 1989;990:113-121.
23. 4H)-ones. Protein Eng. 2001;14:269-278.
24. Cheng TL, Chen BM, Chern JW, et al. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug Chem. 2000;11:258-266.
25. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993; 53:5274-5283.
26. Hirschowitz EA, Ohwada A, Pascal WR, et al. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther. 1995;6:1055-1063.
27. Fick J, Barker II FG, Dazin P, et al. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA. 1995;92:11071-11075.
28. Cheng TL, Wei SL, Chen BM, et al. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. Br J Cancer. 1999;79: 1378-1385.
29. Spooner RA, Martin J, Friedlos F, et al. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug. Cancer Gene Ther. 2000;7:1348-1356.
30. Chen BM, Chan LY, Wang SM, et al. Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats. Int J Cancer. 1997;73:392-402.
31. Chen BM, Cheng TL, Tzou SC, et al. Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy. Int J Cancer. 2001;94:850-858.
32. Leu YL, Roffler SR, Chern JW. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem. 1999; 42:3623-3628.
33. Roffler SR, Chan J, Yeh MY. Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res. 1994;54:1276-1285.
34. Nettelbeck DM, Jerome V, Muller R. Gene therapy: designer promoters for tumour targeting. Trends Genet. 2000;16:174-181.
35. Russell SJ, Cosset FL. Modifying the host range properties of retroviral vectors. J Genet Med. 1999;1:300-311.
36. Wickham TJ. Targeting adenovirus. Gene Therapy. 2000; 7:110-114.